MR Spectroscopy Using Normalized and Non-normalized Metabolite Ratios for Differentiating Recurrent Brain Tumor from Radiation Injury

Academic Radiology

Volumn 18, Issue 9, 2011, Pages 1101-1108

  Elias, Augusto E ^a   Carlos, Ruth C ^a   Smith, Ethan A ^a   Frechtling, Dan ^a   George, Bekris ^a   Maly, Pavel ^b   Sundgren, Pia C ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Brain tumors; Magnetic resonance imaging; Neoplasms; Spectroscopy

Indexed keywords

CHOLINE; CREATINE; N ACETYLASPARTIC ACID;

ADOLESCENT; ADULT; ANAPLASTIC OLIGOASTROCYTOMA; ANAPLASTIC OLIGODENDROMA; ARTICLE; ASTROCYTOMA; BRAIN BIOPSY; BRAIN SURGERY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTRAST ENHANCEMENT; EPENDYMOMA; FEMALE; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; MALE; MEDULLA GLIOMA; METABOLITE; NEUROECTODERM TUMOR; NEUROEPITHELIOMA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIOMA; PONTINE GLIOMA; PRESCHOOL CHILD; PRIMARY TUMOR; PRIMITIVE NEUROECTODERMAL TUMOR; PRIORITY JOURNAL; RADIATION INJURY; RANK SUM TEST; RETROSPECTIVE STUDY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; ASPARTIC ACID; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHOLINE; CREATINE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIATION INJURIES; RETROSPECTIVE STUDIES; ROC CURVE; STATISTICS, NONPARAMETRIC;

EID: 79960972101     PISSN: 10766332     EISSN: 18784046     Source Type: Journal    
DOI: 10.1016/j.acra.2011.05.006     Document Type: Article

References (41)

1. Fulham M.J., Bizzi A., Dieta M.J., et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology 1992, 185:675-686.
2. Weybright P., Sundgren P.C., Gomez-Hassan D., et al. Differentiation of tumor recurrence from treatment related changes using 2D-CSI MR Spectroscopy. Am J Roentgenol AJR 2005, 185:1471-1476.
3. Weybright P., Maly P., Gomez Hassan D., et al. MR spectroscopy in the evaluation of recurrent contrast enhancing lesions in the posterior fossa after tumor treatment. Neuroradiology 2004, 541-549.
4. Rock J.P., Hearschen D., Scarpace L., et al. Correlations between magnetic resonances spectroscopy and imaging-guided histopathology, with special attention to radiation necrosis. Neurosurgery 2002, 51:912-920.
5. Croteau D., Scarpace L., Hearschen D., et al. Correlation between magnetic resonance spectroscopy imaging and image guided biopsies: semiquantitative and qualitative histopathological analyses of patients with untreated gliomas. Neurosurgery 2001, 49:823-829.
6. Dowling C., Bollen A.W., Noworolski S.M., et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol 2001, 22:604-612.
7. Taylor J.S., Langston J.W., Reddick W.E., et al. Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed cerebral necrosis. Int J Radiat Oncol Biol Phys 1996, 36:1251-1261.
8. Zeng Q.S., Li C.F., Zhang K., et al. Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury. J Neurooncol 2007, 84:63-69.
9. Bulakbasi N., Kocaoglu M., Ors F., et al. Combination of single-voxel proton MR spectroscopy and apparent diffusion coefficient calculation in the evaluation of common brain tumors. AJNR Am J Neuroradiol 2003, 24:225-233.
10. Lin A., Bluml S., Mamelak A.N. Efficacy of proton magnetic resonance spectroscopy in clinical decision making for patients with suspected malignant brain tumors. J Neurooncol 1999, 45:69-81.
11. Yang D., Korogi Y., Sugahara T., et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI. Neuroradiology 2002, 44:656-666.
12. Wald L.L., Nelson S.J., Day M.R., et al. Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. J Neurosurg 1997, 87:525-534.
13. Kinoshita K., Tada E., Matsumoto K., et al. Proton MR spectroscopy of delayed cerebral radiation in monkeys and humans after brachytherapy. AJNR Am J Neuroradiol 1997, 18:1753-1761.
14. Rock J.P., Scarpace L., Hearshen D., et al. Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery 2004, 54:1111-1117.
15. Esteve F., Rubin C., Grand S., et al. Transient metabolic changes observed with proton MR spectroscopy in normal human brain after radiation therapy. Int J Radiat Oncol Biol Phys 1998, 15(40):279-286.
16. Lazareff J.A., Gupta R.K., Alger J. Variation of post-treatment H-MRSI choline signal intensity in pediatric gliomas. J Neurooncol 1999, 41:291-298.
17. McKnight T.R., von dem Busche M.H., Vigneron D.B., et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 2002, 97:794-802.
18. Yerli H., Aglidere A.M., Ozen O., et al. Evaluation of cerebral glioma grade by using normal side creatine as an internal reference in multi-voxel 1H-MR spectroscopy. Diagn Interv Radiol 2007, 13:3-9.
19. Tong Z.Y., Toshiaki Y., Wang Y., et al. Proton magnetic resonance spectroscopy of normal human brain and glioma: a quantitative in vivo study. Chin Med J (Engl) 2005, 118:1251-1257.
20. Di Costanzo A., Pollice S., Trojsi F., et al. Role of perfusion-weighted imaging at 3 Tesla in the assessment of malignancy of cerebral gliomas. Radiol Med 2008, 113:134-143.
21. Li C.W., Kuo Y.C., Chen C.Y., et al. Quantification of choline compounds in human hepatic tumors by proton MR spectroscopy at 3 T. Magn Reson Med 2005, 53:770-776.
22. Smith E.A., Carlos R.C., Junck L.R., et al. Developing a clinical decision model: use of MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast enhancing lesions. AJR Am J Roentgenol 2009, 192:W45-W52.
23. Petrou M., Sundgren P.C., Pang Y., et al. Preset versus manually-optimized selection of peak boundaries in calculation of proton metabolite ratios. Acad Radiol 2007, 14:340-343.
24. ROCKIT. Software programs available from the Kurt Rossmann Laboratories. http://xray.bsd.uchicago.edu/krl/KRL_ROC/software_index6.htm.
25. Ando K., Ishikura R., Nagami Y., et al. Usefulness of Cho/Cr ratio in proton MR spectroscopy for differentiating residual/recurrent glioma from non-neoplastic lesions. Nippon Igaku Hoshasen Gakkai Zasshi 2004, 64:121-126. (Article in Japanese).
26. Al-Okaili R.N., Kreja J., Woo J.H., et al. Intra axial brain masses: MR imaging-based diagnostic strategy-initial experience. Radiology 2007, 243:539-550.
27. Law M., Yang S., Wang H., et al. Glioma grading; sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003, 24:1989-1998.
28. Jain R., Scarpace L., Ellika S., et al. First-pass perfusion computed tomography: initial experience in differentiating recurrent brain tumors from radiation effects and radiation necrosis. Neurosurgery 2007, 61:778-786.
29. Terakawa Y., Tsuyuguchi N., Iwai Y., et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 2008, 49:694-699.
30. Sugahara T., Korogi Y., Tomiguchi S., et al. Intra axial brain tumor; the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 2000, 21:901-909.
31. Chan Y.L., Roebuck D.J., Yuen M.P., et al. Long-term cerebral metabolite changes on proton magnetic resonance spectroscopy inpatients cured of acute lymphoblastic leukemia with previous intrathecal methotrexate and cranial irradiation prophylaxis. Int J Radiat Oncol Biol Phys 2001, 50:759-763.
32. Chan Y.L., Yeung D.K.W., Leung S.F., et al. Proton magnetic resonance spectroscopy of late delayed radiation-induced injury of the brain. J Magn Reson Imaging 1999, 10:130-137.
33. Usenius T., Usenius J.P., Tenhunen M., et al. Radiation-induced changes in human brain metabolites as studied by 1H nuclear magnetic resonance spectroscopy in vivo. Int J Radiat Oncol Biol Phys 1995, 33:719-724.
34. Kaminaga T., Shirai K. Radiation-induced brain metabolic changes in the acute and early delayed phase detected with quantitative proton magnetic resonance spectroscopy. J Comp Assist Tomogr 2005, 29:293-297.
35. Movsas B., Li B.S.Y., Babb J.S., et al. Quantifying radiation therapy-induced brain injury with whole brain proton MR spectroscopy: initial observations. Radiology 2001, 221:327-331.
36. 1H-MRS of radiation effects in normal-appearing white matter: Dose-dependence and impact on automated spectral classification. J Magn Reson Imaging 2004, 19:379-388.
37. Sundgren P.C., Nagesh V., Elias A., et al. Metabolic alterations; a biomarker for radiation-induced injury of normal brain. A spectroscopy study. J Magn Reson Imaging 2009, 29:291-297.
38. Li B., Wang H., Gonen O. Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy. J Magn Reson Imaging 2003, 21:923-928.
39. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993, 30:672-679.
40. Hein P.A., Eskey C.J., Dunn J.F., et al. Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 2004, 25:201-209.
41. Bobek-Billewicz B., Stasik-Pres G., Majchrzak H., et al. Differentiation between brain tumor recurrence and radiation injury using perfusion, diffusion-weighted imaging and MR spectroscopy. Folia Neuropathol 2010, 48:81-92.